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BACKGROUND Repeat revascularization following percutaneous
coronary intervention (PCI) is a common end-point in clinical studies
which may reﬂect restenosis, myocardial infarction or stent throm-
bosis events. However, the association between repeat revasculari-
zation and long-term mortality is poorly deﬁned. We explored the
relationship between target vessel revascularization (TVR) and long-
term mortality following PCI.
METHODS We analyzed mortality in 41,180 patients following their
ﬁrst index PCI procedure between 2008-2014 who were enrolled in the
British Columbia Cardiac Registry. Cox proportional hazard models
were built to determine the association between TVR (30 days, 1
month, 6 months, 1 year and 2 years) and long-term mortality at 3
years.
RESULTS A total of 5,554 patients (13.4%) received TVR during the
study period. The TVR rates for 30 days, 3 months, 6 months, 1 year
and 2 years were 2.4%, 3.4%, 4.9%, 6.6% and 8.5% respectively. The 3-
year mortality rates according to whether they had TVR versus no TVR
are shown in table 1. Multivariable-adjusted analyses identiﬁed TVR
at 30 days as a strong predictor for 3-year mortality (HR¼1.64, 95% CI:
1.36-1.98, p<0.001). This association persisted for TVR at 1 year
(HR¼1.17, 95% CI: 1.03-1.33, p¼0.013), but was lost for TVR at 2 years(HR¼1.07, 95% CI: 0.95-1.20, p¼0.269). The trends in HRs are shown in
ﬁgure 1.
CONCLUSIONS In this large cohort of unselected patients undergoing
PCI, early TVR was a strong independent predictor of long-term
mortality. This association became less strong with progressively later
TVR events. These data suggest that TVR events are not benign, and
might help explain late mortality events in clinical studies.
Table 1Follow-up periodCumulative TVR
rate (%)3 year mortality (%)TVR group No TVR group p value30 days 2.4 13.3 7.7 <0.0013 months 3.4 11.9 7.7 <0.0016 months 4.9 11.1 7.6 <0.0011 year 6.6 10.3 7.6 <0.0012 years 8.5 9.3 7.7 0.748CATEGORIES CORONARY: PCI Outcomes
KEYWORDS Mortality, long-term, Percutaneous coronary interven-
tion, Target vessel revascularization
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BACKGROUND The real world generalizability of clinical trials has
come under increasingly intense scrutiny. While patients participating
in clinical trials are of a lower risk proﬁle, they are followed up more
closely post percutaneous coronary intervention (PCI). We wanted to
discern whether enrollment in interventional cardiovascular clinical
trials translates to better or worse outcomes following PCI.
METHODS A single-center analysis was done of patients undergoing
PCI between 1/1/2010 and 12/31/2013 (n ¼ 14,075). Out of this cohort,
4.7% (n ¼ 659) were enrolled in a clinical trial. We compared those
enrolled versus not in clinical trials and analyzed for baseline and
procedural characteristics, death, myocardial infarction (MI), target
vessel revascularization (TVR), and major adverse cardiovascular
events (MACE).
RESULTS Patients enrolled in clinical trials were younger, had a bet-
ter left ventricular ejection fraction (LVEF), lower creatinine, and a
